MedPath

Metacognitive Therapy for Obsessive-Compulsive Disorder

Not Applicable
Recruiting
Conditions
Obsessive-Compulsive Disorder
Interventions
Behavioral: Metacognitive Therapy
Other: General mental health promotion
Registration Number
NCT06466057
Lead Sponsor
Northeast Normal University
Brief Summary

The goal of this clinical trial is to learn if metacognitive therapy can be effective in a Chinese sample of obsessive compulsive disorder (OCD) . The main questions it aims to answer are:

Can metacognitive therapy significantly reduce participants' levels of obsessive-compulsive symptoms? Can metacognitive therapy significantly improve participants' metacognitive adaptations?

The researchers will compare metacognitive therapy to a control condition without psychotherapy to see if metacognitive therapy is effective in treating OCD.

Participants will:

Receive the metacognitive therapy intervention or under control conditions for 8 to 15 weeks.

Be assessed for symptoms and metacognitive beliefs at pre-intervention, post-intervention and 12 weeks post-intervention

Detailed Description

This study will be a randomised controlled clinical trial. Participants who meet the enrolment criteria will be randomised into an experimental group and a control group. Participants in the experimental group will receive 8-15 weeks of metacognitive therapy, while participants in the control group will receive the same amount of time of regular treatment without psychotherapy components.

The researchers will assess participants' obsessive-compulsive symptoms and metacognitive levels before, after, and 12 weeks after the intervention. Assessment measures will be the Yale Brown Obsessive-Compulsive Scale (Y-BOCS) and the Metacognition Questionnaire (MCQ-30).

By comparing the assessment results of the two groups of participants, conclusions will be drawn as to whether metacognitive therapy can have a positive effect on a Chinese OCD sample.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
80
Inclusion Criteria
  • two psychiatrists with the title of Deputy Chief Physician or above jointly determine that the above diagnostic criteria were met
  • education level of junior high school or above, without mental retardation or audio-visual disorders
  • participation in the study is voluntary, and the informed consent is signed by the patient or his/her guardian
Exclusion Criteria
  • loss of or insufficient self-awareness, the presence of hallucinations, delusions, and other psychotic symptoms
  • the presence of severe depression, or self-inflicted suicidal attempts and behaviors
  • the presence of a history of alcohol or drug abuse
  • refusal of psychotherapy, or the ineffectiveness of those who had been involved in a full course of psychotherapy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Metacognitive TherapyMetacognitive TherapyIntervention using metacognitive therapy, with sessions set for 8-15 weeks of 1-2 weekly psychotherapeutic dialogue.
Control ConditionGeneral mental health promotionDo not receive any additional psychotherapy in addition to conventional treatment.
Primary Outcome Measures
NameTimeMethod
Severity of participants' obsessive-compulsive symptomsPre-intervention to 12 weeks post-intervention

Assessed using the Yale Brown Obsessive-Compulsive Scale (Y-BOCS) , with higher scores indicating more severe symptoms.

Secondary Outcome Measures
NameTimeMethod
Levels of Participants' Dysfunctional Metacognitive BeliefsPre-intervention to 12 weeks post-intervention

Assessed using the Metacognition Questionnaire (MCQ-30), with higher scores being associated with more dysfunctional metacognition.

Trial Locations

Locations (1)

Northeast Normal University

🇨🇳

Changchun, Jilin, China

© Copyright 2025. All Rights Reserved by MedPath